What is HC Wainwright’s Forecast for AQST Q1 Earnings?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for Aquestive Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.15) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.11) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million.

A number of other research analysts have also weighed in on AQST. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price on the stock. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a report on Friday, March 7th. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Lake Street Capital reduced their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $10.57.

Aquestive Therapeutics Stock Down 5.6 %

NASDAQ:AQST opened at $2.71 on Monday. Aquestive Therapeutics has a 12-month low of $2.24 and a 12-month high of $5.80. The firm has a market capitalization of $267.94 million, a price-to-earnings ratio of -6.02 and a beta of 2.59. The stock’s 50 day moving average price is $2.97 and its two-hundred day moving average price is $3.87.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AQST. Price T Rowe Associates Inc. MD boosted its stake in shares of Aquestive Therapeutics by 16.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock valued at $99,000 after buying an additional 3,821 shares during the period. MetLife Investment Management LLC grew its holdings in shares of Aquestive Therapeutics by 11.4% during the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company’s stock worth $143,000 after purchasing an additional 4,125 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Aquestive Therapeutics by 10.1% during the 4th quarter. Bank of Montreal Can now owns 54,300 shares of the company’s stock worth $193,000 after purchasing an additional 4,999 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Aquestive Therapeutics by 3.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company’s stock worth $750,000 after purchasing an additional 7,129 shares during the period. Finally, SG Americas Securities LLC raised its stake in Aquestive Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after purchasing an additional 7,347 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.